Online inquiry

IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ766MR)

This product GTTS-WQ766MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets LOXL2 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002318.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4017
UniProt ID Q9Y4K0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ766MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4155MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI-754091
GTTS-WQ4749MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BPS-804
GTTS-WQ6023MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ14380MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ12887MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ9697MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ12361MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ612MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 7F3com-2H2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW